Bladder cancer is a global health issue with sex differences in incidence and prognosis.
Bladder cancer has distinct molecular subtypes with multiple pathogenic pathways …

Over the past decade, various liquid biopsy techniques have emerged as viable alternatives
to the analysis of traditional tissue biopsy samples. Such surrogate 'biopsies' offer numerous …

Background The role of adjuvant chemotherapy in stage II colon cancer continues to be
debated. The presence of circulating tumor DNA (ctDNA) after surgery predicts very poor …

Circulating tumour DNA (ctDNA) assays conducted on plasma are rapidly developing a
strong evidence base for use in patients with cancer. The European Society for Medical …

Minimally invasive approaches to detect residual disease after surgery are needed to
identify patients with cancer who are at risk for metastatic relapse. Circulating tumour DNA …

The field of research in bladder cancer has seen significant advances in recent years. Next-
generation sequencing has identified the genes most mutated in bladder cancer. This …

Importance Bladder cancer is a common malignancy in women and is the fourth most
common malignancy in men. Bladder cancer ranges from unaggressive and usually …

Growing evidence demonstrates that circulating tumor DNA (ctDNA) minimal residual
disease (MRD) following treatment for solid tumors predicts relapse. These results suggest …

Immune checkpoint blockade (ICB) provides clinical benefit to a subset of patients with
cancer. However, existing biomarkers do not reliably predict treatment response across …

Cell-free DNA (cfDNA) derived from tumours is present in the plasma of cancer patients. The
majority of currently available studies on the use of this circulating tumour DNA (ctDNA) deal …